Articles: nausea.
-
Given the growing prevalence of antibiotic resistance globally, there is an urgent need for new therapy options that are effective and well tolerated for treatment of common infections such as bacterial skin infections and pneumonia. Here, we summarize the findings of 3 phase 3 clinical trials of omadacycline, a novel tetracycline-derived aminomethylcycline, in patients with acute bacterial skin and skin structure infections (ABSSSI; OASIS-1 [NCT02378480] and OASIS-2 [NCT02877927]) or community-acquired bacterial pneumonia (CABP; OPTIC [NCT02531438]). The primary endpoint in all studies was early clinical response (early response) at 2 to 3 days (skin studies) or 3 to 5 days (pneumonia study) after the first dose. ⋯ No differences were observed in subgroup analyses, and high rates of clinical response were seen for all treatments against common pathogens. The most frequent adverse event reported was nausea, which was mostly associated with the loading dose in the oral-only regimen in OASIS-2. Overall, omadacycline was well tolerated and showed high rates of clinical response in patients with skin infections and pneumonia, including in those with comorbidities.
-
Postoperative nausea and vomiting is common in patients receiving microvascular decompression. In the current study, we examined whether postoperative nausea and vomiting is associated with reduced intraocular pressure (IOP) after microvascular decompression, a measure that reflects intracranial pressure. ⋯ In patients undergoing microvascular decompression surgery, postoperative IOP reduction is associated with postoperative vomiting.
-
Droperidol is a butyrophenone that has recently been reintroduced after a United States Food and Drug Administration (US FDA) black box warning in 2001. Evidence demonstrates utility in a variety of clinical conditions. ⋯ Current evidence suggests that droperidol is a safe and effective medication for treating nausea and vomiting, headache, vertigo, and agitation in the ED setting.
-
Palliative medicine · Feb 2022
Case ReportsUse of long term aprepitant as a treatment for refractory nausea following oesophageal stent insertion - a case report.
Aprepitant, a substance P neurokinin-1 receptor antagonist, is licenced for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy. ⋯ Further research of neurokinin-1 inhibitors for indications other than chemotherapy-induced nausea and vomiting is indicated.